Organisation paid for research Program year 2022 Source: CMS Open Payments

Community Clinical Research Network

Neither a doctor nor a teaching hospital

Research payments

$631,146

90 payments

Through program year 2022, Community Clinical Research Network is reported as receiving $631,146 in research payments, across 90 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $45,777 5
2021 Research $325,664 50
2020 Research $66,338 9
2019 Research $193,367 26

Breakdown

Who paid Research payments · program years 2019–2022
  1. Biohaven Pharmaceuticals, Inc. $344,933 52 payments
  2. Allergan Inc. $218,369 24 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $45,607 4 payments
  4. Janssen Research & Development, LLC $22,067 9 payments
  5. Roche Products Limited $170 1 payment
Studies the money was for Research payments · program years 2019–2022
  1. BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $219,928 37 payments
  2. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $218,369 24 payments
  3. A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $151,343 17 payments
  4. A Randomized, Double-blind Placebo-controlled and Open label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Obese Subjects $22,067 9 payments
  5. A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $12,033 1 payment
  6. BHV3500-301: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $7,236 1 payment
  7. Crohn S Disease Program Cohort 1 Induction Cohort II Maintenance $170 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record